KF-1607, a novel pan src kinase inhibitor, attenuates obstruction-induced tubulointerstitial fibrosis in mice

Debra Dorotea, Seungyeon Lee, Sun Joo Lee, Gayoung Lee, Jung Beom Son, Hwan Geun Choi, Sung Min Ahn, Hunjoo Ha

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Src family kinases (SFKs), an important group of non-receptor tyrosine kinases, are suggested to be excessively activated during various types of tissue fibrosis. The present study investigated the effect of KF-1607, an orally active and a newly synthesized Src kinase inhibitor (SKI) with proposed low toxicity, in preventing the progression of renal interstitial fibrosis. Unilateral ureteral obstruction (UUO) surgery was performed in 6-week-old male C57BL/6 mice to induce renal interstitial fibrosis. Either KF-1607 (30 mg/kg, oral gavage) or PP2 (2 mg/kg, intraperitoneal injection), a common experimental SKI, was administered to mice for seven days, started one day prior to surgery. UUO injury-induced SFK expression, including Src, Fyn, and Lyn kinase. SFK inhibition by KF-1607 prevented the progression of tubular injury in UUO mice, as indicated by decreases in albuminuria, urinary KIM-1 excretion, and kidney NGAL protein expression. Renal tubulointerstitial fibrosis was attenuated in response to KF-1607, as shown by decreases in α-SMA, collagen I and IV protein expression, along with reduced Masson’s trichrome and collagen-I staining in kidneys. KF-1607 also inhibited inflammation in the UUO kidney, as exhibited by reductions in F4/80 positive-staining and protein expression of p-NFκB and ICAM. Importantly, the observed effects of KF-1607 were similar to those of PP2. A new pan Src kinase inhibitor, KF-1607, is a potential pharmaceutical agent to prevent the progression of renal interstitial fibrosis.

Original languageEnglish
Pages (from-to)41-51
Number of pages11
JournalBiomolecules and Therapeutics
Issue number1
StatePublished - 2021

Bibliographical note

Funding Information:
We thank Junghwa Lee for her excellent technical assistance. This work was supported by grants from the Korean Health Technology R&D Project through the Korean Health Industry Development Institute (HI18C0695).

Publisher Copyright:
© 2021 The Korean Society of Applied Pharmacology.


  • Chronic kidney disease
  • Renal fibrosis
  • Src kinase
  • Src kinase inhibitor
  • Ureteral obstruction


Dive into the research topics of 'KF-1607, a novel pan src kinase inhibitor, attenuates obstruction-induced tubulointerstitial fibrosis in mice'. Together they form a unique fingerprint.

Cite this